GO:1903025 regulation of RNA polymerase II regulatory region sequence-specific DNA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903025 describes any process that modulates the frequency, rate or extent of sequence-specific DNA binding by RNA polymerase II regulatory region-binding proteins.
• It sits at the top of eukaryotic gene control because sequence-specific DNA-binding proteins govern messenger RNA synthesis.
• The process is executed by transcription factors, cofactors and chromatin-associated complexes that assemble on promoters and enhancers.
• Histone H1 and other chromatin proteins can repress basal RNA polymerase II transcription, and antirepression restores sequence-specific DNA binding.
• Histone H3 lysine 4 methylation and other chromatin marks influence how transcription factors access regulatory DNA.
• Dysregulation of this process is linked to cancer, developmental disorders and transcriptional addiction, making it a major drug-target class.
Description
GO:1903025, regulation of RNA polymerase II regulatory region sequence-specific DNA binding, is a biological_process term that captures how cells control the binding of proteins to RNA polymerase II regulatory regions such as promoters and enhancers. Sequence-specific DNA-binding proteins were recognized decades ago as the central controllers of eukaryotic messenger RNA synthesis, and their regulated occupancy of regulatory DNA determines which genes are expressed. Because RNA polymerase II itself does not select promoters, the frequency and extent of sequence-specific DNA binding by transcription factors and associated factors is a decisive step in gene regulation. The term therefore matters for any researcher asking how a promoter or enhancer is turned on, kept off, or reset during development, differentiation or disease. Experimental work has shown that this regulation can be reconstituted and visualized in real time at single promoters, revealing activation mechanisms that were previously inferred only indirectly. It is also a process that can be inhibited by synthetic DNA-binding ligands, demonstrating that sequence-specific DNA binding is a chemically tractable step in human cells.
regulation of RNA polymerase II regulatory region sequence-specific DNA binding At A Glance
| GO ID | GO:1903025 |
|---|---|
| GO term | regulation of RNA polymerase II regulatory region sequence-specific DNA binding |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of sequence-specific DNA binding at RNA polymerase II regulatory regions |
| Biological context | Promoter and enhancer control of eukaryotic messenger RNA synthesis |
| Key molecular players | Sequence-specific transcription factors, coactivators, corepressors and chromatin proteins |
| Regulatory layer | Chromatin modification, including histone H3 lysine 4 methylation, and histone H1-mediated repression |
| Experimental tractability | Reconstituted transcription, single-promoter imaging and synthetic DNA-binding ligands |
What Is GO:1903025?
In plain terms, GO:1903025 is the set of processes that adjust how often, how fast or how strongly a protein binds to a specific DNA sequence within an RNA polymerase II regulatory region. The QuickGO definition states: any process that modulates the frequency, rate or extent of RNA polymerase II regulatory region sequence-specific DNA binding. It does not describe the binding event itself; it describes the regulatory inputs that change that binding, such as transcription factor availability, cofactor recruitment, chromatin state and antirepression of basal transcription.
Why Is regulation of RNA polymerase II regulatory region sequence-specific DNA binding Important in Cell Biology?
GO:1903025 is important because the regulated binding of sequence-specific proteins to RNA polymerase II regulatory regions is the point at which most eukaryotic gene expression decisions are made. If this regulation fails, cells can lose control of proliferation, differentiation or stress responses, and the same step is a validated target for synthetic ligands and transcriptional inhibitors. Understanding it also requires integrating transcription factor biochemistry, chromatin biology and real-time transcription dynamics, which is why it remains a central problem in molecular biology.
• It controls the first committed step of RNA polymerase II transcription at specific promoters and enhancers.
• It determines cell-type-specific gene expression programs during development and differentiation.
• It is modulated by chromatin marks such as histone H3 lysine 4 methylation.
• It can be repressed by histone H1 and restored by sequence-specific antirepression.
• It is a target of synthetic DNA-binding ligands that inhibit RNA polymerase II transcription in human cells.
• It can be studied in real time at single promoters using reconstituted transcription systems.
• It is relevant to cancer because transcriptional addiction and oncogenic transcription factors depend on regulatory-region binding.
• It is relevant to developmental disorders caused by mutations in transcription factors and chromatin regulators.
• It provides a mechanistic framework for interpreting non-coding regulatory variants in disease.
• It connects archaeal and eukaryotic chromatin-transcription principles, highlighting deep evolutionary conservation.
What Happens During regulation of RNA polymerase II regulatory region sequence-specific DNA binding?
Recognition of regulatory DNA by sequence-specific factors
In simple terms: Proteins scan DNA and lock onto specific short sequences in promoters and enhancers.
The process begins when sequence-specific DNA-binding proteins recognize cognate elements within RNA polymerase II regulatory regions. These proteins do not bind randomly; their affinity and selectivity for particular sequences determine which regulatory regions are occupied. The frequency and extent of this binding are themselves regulated, which is the essence of GO:1903025. Structural and biochemical studies of transcription factor-DNA interactions have defined how these proteins read out regulatory sequences and how their occupancy can be modulated.
Assembly of multi-protein transcription complexes
In simple terms: Once bound, factors recruit many partner proteins that build the transcription machine.
Sequence-specific factors nucleate the assembly of multi-protein complexes that include coactivators, corepressors, chromatin modifiers and general transcription factors. These complexes change the local chromatin environment and either stabilize or destabilize factor binding to regulatory DNA. The composition of these complexes therefore directly modulates the frequency and extent of sequence-specific DNA binding at RNA polymerase II regulatory regions.
Chromatin-dependent repression and antirepression
In simple terms: Chromatin proteins can block transcription, and antirepression removes that block.
Histone H1 and other chromatin proteins can inhibit basal RNA polymerase II transcription by restricting access to regulatory DNA. Sequence-specific antirepression counteracts this inhibition and restores binding and transcription. This balance between repression and antirepression is a core mechanism by which GO:1903025 is executed. Chromatin marks such as histone H3 lysine 4 methylation further tune this balance by influencing how factors access regulatory regions.
Real-time activation at single promoters
In simple terms: Modern imaging shows how a single promoter switches on step by step.
Reconstituted transcription systems have enabled real-time visualization of RNA polymerase II activation at single promoters. These experiments reveal the kinetic steps through which regulatory-region binding leads to productive transcription. Such single-promoter resolution is important because population assays average over heterogeneous binding events that are the subject of GO:1903025. The approach also helps distinguish changes in binding frequency from changes in binding stability.
Chemical and synthetic modulation of regulatory-region binding
In simple terms: Small molecules can be designed to interfere with sequence-specific DNA binding.
Synthetic DNA-binding ligands can inhibit RNA polymerase II transcription in human cells, showing that sequence-specific DNA binding is a druggable step. These ligands compete with or distort the interactions that normally regulate factor occupancy at regulatory regions. Their effects provide functional evidence that modulating this binding is sufficient to change transcription output. This connects GO:1903025 to therapeutic strategies aimed at transcriptional control.
Key Genes Involved in GO:1903025 regulation of RNA polymerase II regulatory region sequence-specific DNA binding
The genes and proteins most relevant to GO:1903025 are sequence-specific transcription factors, coactivators, corepressors, chromatin proteins and RNA polymerase II-associated factors that together regulate binding to RNA polymerase II regulatory regions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Sequence-specific transcription factor that binds promoter elements of target genes | Model for studying regulated promoter occupancy in stress responses |
| MYC | Sequence-specific transcription factor controlling growth-related regulatory regions | Central to transcriptional addiction and cancer models |
| JUN | Component of AP-1 sequence-specific transcription factor complexes | Prototype for studying enhancer binding and cofactor recruitment |
| FOS | AP-1 family sequence-specific factor | Used to dissect stimulus-dependent regulatory-region binding |
| SP1 | GC-box binding factor at many RNA polymerase II promoters | Classic model for basal promoter occupancy |
| CTCF | Architectural DNA-binding protein at regulatory boundaries | Relevant to chromatin looping and regulatory-region accessibility |
| H1-4 | Linker histone that represses basal RNA polymerase II transcription | Direct experimental handle on repression and antirepression |
| TBP | TATA-box binding protein within general transcription machinery | Links sequence-specific binding to polymerase recruitment |
| GTF2B | General transcription factor TFIIB | Core component of the transcription preinitiation complex |
| GTF2E2 | General transcription factor TFIIE subunit | Used to study preinitiation complex assembly |
| MED1 | Mediator coactivator subunit | Connects enhancer-bound factors to RNA polymerase II |
| EP300 | Histone acetyltransferase coactivator | Modifies chromatin to modulate regulatory-region binding |
| CREBBP | Histone acetyltransferase coactivator | Parallels EP300 in enhancer regulation |
| KMT2A | Histone H3 lysine 4 methyltransferase | Directly links H3K4 methylation to regulatory-region function |
| KDM5A | Histone H3 lysine 4 demethylase | Reverses H3K4 methylation and modulates transcription |
| POLR2A | Largest subunit of RNA polymerase II | Readout of regulatory-region activation |
| CDK9 | Kinase associated with positive transcription elongation factor b | Couples regulatory-region binding to elongation control |
How Is regulation of RNA polymerase II regulatory region sequence-specific DNA binding Regulated?
GO:1903025 is itself regulated at multiple levels. Chromatin structure and histone modifications, especially histone H3 lysine 4 methylation, influence whether sequence-specific factors can access RNA polymerase II regulatory regions. Histone H1-mediated repression can be reversed by sequence-specific antirepression, providing a direct regulatory switch. The availability and post-translational modification of transcription factors and cofactors determine the composition of multi-protein complexes at regulatory regions. In addition, synthetic DNA-binding ligands can acutely modulate this process, demonstrating that it is responsive to chemical perturbation. Real-time single-promoter studies show that activation is kinetically controlled, with distinct steps that can be independently regulated.
regulation of RNA polymerase II regulatory region sequence-specific DNA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYC | Oncogenic transcriptional addiction | Knockout or point-mutation cell models with regulatory-region binding assays |
| TP53 | Tumor suppression and stress-response transcription | Knock-in of patient mutations followed by promoter occupancy analysis |
| KMT2A | Leukemia and developmental disorders linked to H3K4 methylation | Knockout and catalytic-dead knock-in models |
| H1-4 | Chromatin repression and transcriptional dysregulation | Overexpression and knockout models for antirepression studies |
| EP300 | Cancer and developmental syndromes | Knockout and tagged knock-in for coactivator recruitment assays |
Cancer and transcriptional addiction
Many cancers depend on sustained sequence-specific DNA binding at RNA polymerase II regulatory regions to drive oncogenic gene expression programs. Oncogenic transcription factors such as MYC and AP-1 family members rely on regulated occupancy of promoters and enhancers, and disrupting this regulation can reduce tumor cell proliferation. Because synthetic DNA-binding ligands can inhibit RNA polymerase II transcription in human cells, this process is a candidate target for transcriptional therapy.
Developmental disorders and chromatinopathies
Mutations in transcription factors and chromatin regulators that control regulatory-region binding can cause developmental disorders. Histone H3 lysine 4 methylation pathways are particularly important because they directly influence how factors access regulatory DNA. Disruption of repression and antirepression balance by histone H1 or its regulators can also alter developmental gene expression programs.
Non-coding regulatory variants and complex disease
Non-coding variants in promoters and enhancers can change the frequency or extent of sequence-specific DNA binding, thereby altering gene expression in complex diseases. Interpreting these variants requires mechanistic knowledge of how transcription factors and cofactors assemble at regulatory regions. Functional assays that measure regulatory-region binding are therefore increasingly used to link non-coding variation to disease phenotypes.
From regulation of RNA polymerase II regulatory region sequence-specific DNA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate factor regulate promoter occupancy? | Knockout cell model with ChIP-based binding assays |
| Does a specific residue control regulatory-region binding? | Point-mutation knock-in at the endogenous locus |
| Does a chromatin mark reader modulate binding? | Tagged knock-in of the reader domain |
| Is overexpression sufficient to drive transcription? | Doxycycline-inducible overexpression cell model |
| Can a synthetic ligand disrupt binding? | Wild-type cells treated with DNA-binding ligands |
| What are the real-time kinetics of activation? | Reconstituted single-promoter transcription system |
How to Study the regulation of RNA polymerase II regulatory region sequence-specific DNA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide factor occupancy at regulatory regions | Mapping transcription factor binding changes |
| Single-promoter imaging | Real-time activation kinetics | Dissecting stepwise RNA polymerase II activation |
| Histone modification profiling | Chromatin marks such as H3K4 methylation | Linking chromatin state to regulatory-region binding |
| DNA-binding ligand assays | Acute inhibition of sequence-specific transcription | Chemical validation of binding dependence |
| Reporter assays | Transcriptional output from defined regulatory regions | Testing promoter and enhancer variants |
| Co-immunoprecipitation | Multi-protein complex composition | Identifying cofactors at regulatory regions |
| In vitro reconstitution | Minimal requirements for regulated binding | Defining biochemical mechanism |
| CRISPR knockout screens | Genes required for regulatory-region binding | Discovering modulators of the process |
Chromatin immunoprecipitation and binding assays
ChIP, ChIP-seq and related assays measure where sequence-specific factors and cofactors occupy RNA polymerase II regulatory regions. These methods are the primary readout for changes in the frequency and extent of regulatory-region binding. They can be combined with knockout or point-mutation models to test causality.
Real-time single-promoter transcription imaging
Reconstituted transcription systems allow real-time visualization of RNA polymerase II activation at individual promoters. This approach resolves kinetic steps that are invisible in population assays. It is especially useful for distinguishing changes in binding frequency from changes in binding duration.
Chromatin and histone modification profiling
Profiling histone H3 lysine 4 methylation and other marks reveals how chromatin states influence regulatory-region binding. These measurements complement factor-occupancy data by showing whether regulatory DNA is accessible. They are also used to interpret the effects of chromatin-modifying enzyme knockouts.
Chemical perturbation with DNA-binding ligands
Synthetic DNA-binding ligands can be used to acutely inhibit RNA polymerase II transcription in human cells. This provides a chemical genetics approach to test whether a phenotype depends on sequence-specific DNA binding. Dose-response and time-course experiments can reveal the kinetic sensitivity of the process.
How CRISPR Can Be Used to Study GO:1903025 regulation of RNA polymerase II regulatory region sequence-specific DNA binding
Knockout
CRISPR knockout of candidate transcription factors, cofactors or chromatin regulators can test whether they are required for sequence-specific DNA binding at RNA polymerase II regulatory regions. Knockout models are typically combined with ChIP-based occupancy assays to measure changes in binding frequency or extent. This approach is well suited to identifying essential modulators of GO:1903025.
Point Mutation
Point-mutation knock-in can dissect which residues of a DNA-binding domain or cofactor interface are required for regulated binding. Such models avoid the confounding effects of complete protein loss and can reveal separation-of-function phenotypes. They are particularly useful for testing disease-associated missense variants in transcription factors.
Knock-in
Tagged knock-in of transcription factors, cofactors or histone readers enables endogenous-locus imaging and pulldown assays. These models preserve physiological expression levels and are ideal for studying how regulatory-region binding is modulated in real time. Knock-in of reporter cassettes at regulatory regions can also provide a direct transcriptional readout.
Overexpression
Overexpression models test whether increasing the dose of a factor is sufficient to change regulatory-region binding and transcription. Inducible systems allow time-resolved analysis of binding and activation. Overexpression is often used in parallel with knockout to establish sufficiency and necessity.
How EDITGENE Supports regulation of RNA polymerase II regulatory region sequence-specific DNA binding Research
Researchers studying regulation of RNA polymerase II regulatory region sequence-specific DNA binding-related genes often need to determine whether a candidate gene is causally involved in controlling factor occupancy at promoters and enhancers, rather than merely correlating with it. Establishing causality requires precise genetic models in which the candidate gene can be removed, mutated, tagged or overexpressed at controlled levels. EDITGENE provides these models together with screening and bioinformatics support so that regulatory-region binding hypotheses can be tested rigorously.
Contact EDITGENE today to design your custom CRISPR model for regulation of RNA polymerase II regulatory region sequence-specific DNA binding research.
Frequently Asked Questions About regulation of RNA polymerase II regulatory region sequence-specific DNA binding
What is GO:1903025?
GO:1903025 is the biological_process term regulation of RNA polymerase II regulatory region sequence-specific DNA binding, defined as any process that modulates the frequency, rate or extent of RNA polymerase II regulatory region sequence-specific DNA binding.
What does regulation of RNA polymerase II regulatory region sequence-specific DNA binding mean in simple terms?
It means the set of cellular processes that change how often, how fast or how strongly a protein binds to a specific DNA sequence in a promoter or enhancer used by RNA polymerase II.
What genes are involved in regulation of RNA polymerase II regulatory region sequence-specific DNA binding?
Key genes include sequence-specific transcription factors such as TP53, MYC, JUN, FOS and SP1, coactivators such as EP300 and CREBBP, chromatin regulators such as KMT2A and KDM5A, and general transcription factors such as TBP and GTF2B.
Why is sequence-specific DNA binding important for RNA polymerase II transcription?
Sequence-specific DNA-binding proteins control eukaryotic messenger RNA synthesis by selecting which regulatory regions are active, making their regulated binding a decisive step in gene expression.
How is histone H1 involved in this process?
Histone H1 can inhibit basal RNA polymerase II transcription, and sequence-specific antirepression reverses this inhibition to restore regulatory-region binding and transcription.
Does histone H3 lysine 4 methylation affect regulatory-region binding?
Yes, histone H3 lysine 4 methylation is a chromatin mark that influences how transcription factors and cofactors access RNA polymerase II regulatory regions.
Can small molecules modulate sequence-specific DNA binding?
Yes, synthetic DNA-binding ligands can inhibit RNA polymerase II transcription in human cells, showing that this step is chemically tractable.
How can I study this process experimentally?
Common approaches include ChIP-seq for factor occupancy, single-promoter imaging for real-time kinetics, histone modification profiling for chromatin state, and DNA-binding ligand assays for chemical perturbation.
What CRISPR models are useful for studying GO:1903025?
Knockout, point-mutation, knock-in and overexpression models are all useful; knockouts test necessity, point mutations dissect domains, knock-ins preserve physiological regulation, and overexpression tests sufficiency.
Is GO:1903025 relevant to disease?
Yes, dysregulated regulatory-region binding is linked to cancer, developmental disorders and complex disease through non-coding regulatory variants.
Conclusion
GO:1903025 provides a precise ontology handle for the regulatory inputs that control sequence-specific DNA binding at RNA polymerase II promoters and enhancers. Its mechanisms span transcription factor recognition, multi-protein complex assembly, chromatin-dependent repression and antirepression, and real-time activation kinetics. Because this process is central to gene expression and is chemically and genetically tractable, it remains a high-value area for both basic and translational research.
References
- 1. Palacio M et al.. 2025. Real-time visualization of reconstituted transcription reveals RNAPII activation mechanisms at single promoters.. Cell Rep 44(9):116251 PMID: 40914943
- 2. Chen H et al.. 2021. What do Transcription Factors Interact With?. J Mol Biol 433(14):166883 PMID: 33621520
- 3. Croston GE et al.. 1991. Sequence-specific antirepression of histone H1-mediated inhibition of basal RNA polymerase II transcription.. Science 251(4994):643-9 PMID: 1899487
- 4. Dynan WS et al.. 1985. Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins.. Nature 316(6031):774-8 PMID: 4041012
- 5. Lüscher B et al.. 2025. Role of Histone H3 Lysine 4 Methylation in Chromatin Biology.. Molecules 30(20) PMID: 41157092
- 6. Dickinson LA et al.. 1998. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands.. Proc Natl Acad Sci U S A 95(22):12890-5 PMID: 9789010
- 7. Martinez E. 2002. Multi-protein complexes in eukaryotic gene transcription.. Plant Mol Biol 50(6):925-47 PMID: 12516863
- 8. Reeve JN. 2003. Archaeal chromatin and transcription.. Mol Microbiol 48(3):587-98 PMID: 12694606
